To read the full story, subscribe or sign in.

Alnylam Bringing In $101M, Gearing Up For Second IND

Dec. 14, 2006

On the heels of a stock surge that began when RNAi competitor Sirna Therapeutics Inc. received a hefty buyout offer from Merck & Co. Inc., Alnylam Pharmaceuticals Inc. is raising $101 million through the sale of common stock. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...